What is the endocannabinoid system?
If you have read anything about CBD, you have probably encountered the term "endocannabinoid system" mentioned in passing before the article moves on to telling you which product to buy. Let us actually explain what it is, because understanding this system is the foundation for understanding everything else about how CBD interacts with your body.
The endocannabinoid system (ECS) is a biological signalling system present in all mammals. It was discovered in the early 1990s by researchers who were studying how THC produces its effects — which tells you something about how recently we have come to understand this part of our own biology. We have known about the digestive system for centuries. We have known about the endocannabinoid system for roughly thirty years.
The ECS consists of three core components.
Endocannabinoids are cannabinoids that your body produces naturally. The two primary endocannabinoids identified so far are anandamide (AEA) and 2-arachidonoylglycerol (2-AG). The name anandamide comes from the Sanskrit word "ananda," meaning bliss — which gives you some indication of its function. These are not substances you consume. Your body manufactures them on demand.
Receptors are the sites where cannabinoids bind to produce their effects. The two main receptor types are CB1 receptors, which are concentrated in the central nervous system (brain and spinal cord), and CB2 receptors, which are found primarily in the peripheral nervous system and immune cells. CB1 receptors are among the most abundant receptor types in the human brain.
Enzymes break down endocannabinoids after they have done their job. The two key enzymes are FAAH (fatty acid amide hydrolase), which breaks down anandamide, and MAGL (monoacylglycerol lipase), which breaks down 2-AG. This is an important detail — the ECS operates on demand. Endocannabinoids are synthesised when needed and broken down afterwards, rather than being stored for later use.
What does the ECS actually do?
The ECS is involved in regulating a remarkably wide range of physiological processes. These include mood, sleep, appetite, pain perception, immune function, inflammation, memory, and reproductive function.
The underlying principle is homeostasis — the maintenance of internal stability. When something in your body moves outside its normal operating range, the ECS helps bring it back. Think of it as a balancing system that operates across multiple biological functions simultaneously.
This is why cannabinoids appear to have such a broad range of potential effects. They are not targeting one specific pathway in the way that, say, an antihistamine targets histamine receptors. They are interacting with a system that touches almost everything.
How CBD interacts with the ECS
Here is where much of the marketing material gets it wrong, and where the science becomes genuinely interesting.
CBD does not bind directly to CB1 or CB2 receptors in the way that THC does. This is the fundamental reason why CBD does not produce a psychoactive "high." THC fits into CB1 receptors like a key in a lock and activates them directly. CBD does not.
Instead, CBD appears to work through several indirect mechanisms.
FAAH inhibition. CBD may inhibit the FAAH enzyme, which is responsible for breaking down anandamide. If FAAH is less active, your natural anandamide stays in circulation longer and at higher concentrations. This is sometimes described as CBD helping your body make better use of its own endocannabinoids rather than introducing external ones.
Serotonin receptor interaction. CBD has been shown to interact with 5-HT1A serotonin receptors. Serotonin is a neurotransmitter heavily involved in mood regulation, and 5-HT1A is a receptor subtype associated with anxiety. This interaction may explain the anxiolytic (anxiety-reducing) effects that have been observed in both preclinical and some clinical studies.
Allosteric modulation of CB1. Rather than activating CB1 receptors directly, CBD appears to act as a negative allosteric modulator. In practical terms, this means it may change the shape of the CB1 receptor slightly, making it less responsive to other cannabinoids — including THC. This is one proposed explanation for why CBD may reduce some of the unwanted effects of THC.
Additional receptor targets. Research has identified CBD interactions with TRPV1 receptors (involved in pain perception and inflammation), GPR55 receptors (sometimes called the "orphan receptor," involved in bone density and blood pressure), and PPAR-gamma receptors (involved in metabolic function). The full picture of CBD's receptor activity is still being mapped.
The key word throughout all of this is "may." The research is promising and the mechanisms are plausible, but much of the evidence remains preclinical — meaning it comes from cell studies and animal models rather than large-scale human clinical trials.
The entourage effect
You will frequently encounter the claim that full-spectrum CBD products are superior to isolate products because of the "entourage effect." This concept suggests that the various compounds in the cannabis plant — cannabinoids, terpenes, flavonoids — work synergistically, producing greater effects together than any single compound would alone.
There is preclinical evidence supporting this idea. A 2011 review by Ethan Russo examined the potential synergistic interactions between cannabinoids and terpenes, finding plausible mechanisms for enhanced therapeutic effects.
However, it is important to be precise about the strength of this evidence. The entourage effect is a reasonable hypothesis with some supporting data, but it is not an established fact proven by large-scale clinical trials. The difference matters when you are choosing a product.
Why different people respond differently
Understanding the ECS also helps explain a common frustration: why CBD seems to work well for some people and barely at all for others.
Your endocannabinoid tone — the baseline level of endocannabinoid activity in your body — varies from person to person. Genetics, diet, exercise, stress levels, and overall health all influence how your ECS functions. Someone with naturally low endocannabinoid tone might respond more noticeably to supplemental cannabinoids than someone whose system is already functioning optimally.
This individual variation also explains why dosage is not straightforward. Unlike paracetamol, where there is a well-established effective dose for the general population, the optimal CBD dose likely depends on your individual ECS activity, body composition, metabolism, and the specific issue you are trying to address.
The honest summary
The endocannabinoid system is real, well-documented science. It is not a marketing invention. CBD's interaction with this system is plausible and supported by a growing body of evidence, including identified receptor targets and proposed mechanisms of action.
However, we are still in the relatively early stages of understanding exactly how it all works in practice. The preclinical evidence is strong. The clinical evidence is growing but not yet conclusive for most applications.
Anyone who tells you CBD "definitely" does something specific is overstating the evidence. Anyone who tells you it is "definitely" useless is ignoring it. The truth, as is usually the case in science, sits somewhere in the middle — and the research is ongoing.